Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 674-681

  Hosing, Chitra ^a   Nash, Richard ^b   McSweeney, Peter ^c   Mineishi, Shin ^d   Seibold, James ^e   Griffith, Linda M ^f   Shulman, Howard ^b   Goldmuntz, Ellen ^f   Mayes, Maureen ^g   Parikh, Chirag R ^h   Crofford, Leslie ⁱ   Keyes Elstein, Lynette ^j   Furst, Daniel ^k   Steen, Virginia ^l   Sullivan, Keith M ^m  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Rocky Mountain Cancer Center   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h YALE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j RHO INC   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l GEORGETOWN UNIVERSITY   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Renal complications; Scleroderma

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEART TAMPONADE; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; LUNG HEMORRHAGE; MALE; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NEOPLASM; PLASMAPHERESIS; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SCLERODERMA; SYSTEMIC SCLEROSIS; UNITED STATES; WHOLE BODY RADIATION;

ACUTE KIDNEY INJURY; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK FACTORS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES; WHOLE-BODY IRRADIATION;

EID: 79954580851     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.003     Document Type: Article

References (51)

1. Steen V.D., Syzd A., Johnson J.P., et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005, 32:649-655.
2. Denton C.P. Renal manifestations of systemic sclerosis: clinical features and outcome assessment. Rheumatology (Oxford) 2008, 47(Suppl 5):54-56.
3. Walker U.A., Tyndall A., Czirjak L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007, 66:754-763.
4. Kersting S., Verdonck L.F. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant 2007, 13:638-643.
5. Kersting S., Dorp S.V., Theobald M., et al. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008, 14:125-131.
6. Saddadi F, Najafi I, Hakemi MS, et al. Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran. Iran J Kidney Dis. 2010;4:20-26.
7. Parikh C.R., Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 2006, 69:430-435.
8. Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:976-984.
9. Zager R.A., O'Quigley J., Zager B.K., et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989, 13:210-216.
10. Nash R.A., McSweeney P.A., Crofford L.J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007, 110:1388-1396.
11. Nash R.A., McSweeney P.A., Nelson J.L., et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum 2006, 54:1982-1986.
12. Craciunescu O.I., Steffey B.A., Kelsey C.R., et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation on the SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial. Int J Radiat Oncol Biol Physics 2010, in press.
13. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
14. Borg M., Hughes T., Horvath N., et al. Renal toxicity after total body irradiation. Int J Radiat Oncol Biol Phys 2002, 54:1165-1173.
15. Van Why S.K., Friedman A.L., Wei L.J., et al. Renal insufficiency after bone marrow transplantation in children. Bone Marrow Transplant 1991, 7:383-388.
16. Kal H.B., Loes van Kempen-Harteveld M., Heijenbrok-Kal M.H., et al. Biologically effective dose in total-body irradiation and hematopoietic stem cell transplantation. Strahlenther Onkol 2006, 182:672-679.
17. Kal H.B., van Kempen-Harteveld M.L. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys 2006, 65:1228-1232.
18. Levine J.M., Lien Y.H. Antithymocyte globulin-induced acute renal failure. Am J Kidney Dis 1999, 34:1155. (letter).
19. Wu I., Parikh C.R. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol 2008, 3:1895-1901.
20. Binks M., Passweg J.R., Furst D., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001, 60:577-584.
21. Vonk M.C., Marjanovic Z., van den Hoogen F.H., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67:98-104.
22. Farge D., Passweg J., van Laar J.M., et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004, 63:974-981.
23. Haviv Y.S., Safadi R. Normotensive scleroderma renal crisis: case report and review of the literature. Renal Fail 1998, 20:733-736.
24. Teixeira L., Mahr A., Berezne A., et al. Scleroderma renal crisis, still a life-threatening complication. Ann NY Acad Sci 2007, 1108:249-258.
25. Teixeira L., Mouthon L., Mahr A., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008, 67:110-116.
26. Steen V.D., Costantino J.P., Shapiro A.P., et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin-converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113:352-357.
27. Steen V.D., Medsger T.A. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000, 133:600-603.
28. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
29. DeMarco P.J., Weisman M.H., Seibold J.R., et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002, 46:2983-2989.
30. Strand V. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002, 46:2836-2837.
31. Miralbell R., Bieri S., Mermillod B., et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total body irradiation and graft-versus-host disease. J Clin Oncol 1996, 14:579-585.
32. Cheng J.C., Schultheiss T.E., Wong J.Y. Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation. Int J Radiat Oncol Biol Phys 2008, 71:1436-1443.
33. Rabinowe S.N., Soiffer R.J., Tarbell N.J., et al. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood 1991, 77:1837-1844.
34. Krochak R.J., Baker D.G. Radiation nephritis: clinical manifestations and pathophysiologic mechanisms. Urology 1986, 27:389-393.
35. Iacopino P., Pucci G., Arcese W., et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999, 24:47-51.
36. Holler E., Kolb H.J., Hiller E., et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989, 73:2018-2024.
37. Ho V.T., Cutler C., Carter S., et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:571-575.
38. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007, 92:95-100.
39. Elliott M.A., Nichols W.L., Plumhoff E.A., et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003, 78:421-430.
40. Choi C.M., Schmaier A.H., Snell M.R., et al. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009, 69:183-198.
41. Vesely S.K., George J.N., Lammle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102:60-68.
42. Batts E.D., Lazarus H.M. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?. Bone Marrow Transplant 2007, 40:709-719.
43. Moake J.L. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004, 41:4-14.
44. Hovinga J.A., Studt J.D., Alberio L., et al. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004, 41:75-82.
45. Rock G.A. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000, 109:496-507.
46. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347:589-600.
47. Manadan A.M., Harris C., Block J.A. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 2005, 34:683-688.
48. Nanke Y., Akama H., Yamanaka H., et al. Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy. Am J Med Sci 2000, 320:348-351.
49. Kapur A., Ballou S.P., Renston J.P., et al. Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol 1997, 24:2469-2472.
50. Sullivan K.M., Muraro P., Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Biol Blood Marrow Transplant 2010, 16:S48-S56.
51. Hoste E.A., Clermont G., Kersten A., et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006, 10:R73. (editorial).